Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

AI judging. Sports betting. Fantasy sports. And soon, a year-round, team-based league format. It’s a brave new world for X Games, and under majority owner MSP Sports Capital and new CEO Jeremy ...

Red Dead Redemption 2 lacks a contract killing mode ... "How would you explain it in game?" It's valid to point out that contract killing would be totally against a High Honor Arthur playthrough ...

In one of those matchups, the Canadiens lost to the Kings. Here are the results and highlights from the other two games. This was the 50th game-winning goal of the American’s career, who will ...

Desperate Silksong fans believe a new ARG hinting at the long-awaited game's release date has begun, involving the Nintendo Switch 2 and a slice of cake. Let's break it down. Two days ago ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

Google released Gemini 2.0 Flash for Google AI Studio and Vertex AI. The “Flash” in this model’s name means that it’s a model focused on speed. You’ll want to use this model if you want ...

A second T1D program, VX-264, is in a phase 1/2 study. In the meantime, Vertex enjoys a monopoly in treating the underlying cause of CF. Newly approved Alyftrek will likely become the company's ...